Praxis Precision Medicines, Inc.
Close on Oct 19, 2026
- Market cap
- $7.58B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | – | $-2.87 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | During market hours | – | $-3.20 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 19, 2026 | Before market open | – | $-3.50 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | Before market open | $0 | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 4, 2025 | Before market open | – | $-3.31 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 2, 2025 | Before market open | – | $-3.29 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 29, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | Before market open | $300.00K | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | Before market open | $400.00K | $-1.74 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 5, 2024 | Before market open | – | – | – |
Press releases
Announcements Praxis Precision Medicines filed with the SEC
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
7 MOVEMENT DISORDERS: Ulixacaltamide for Essential Tremor
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
7 MOVEMENT DISORDERS: Ulixacaltamide for Essential Tremor
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
CORPORATE OVERVIEW October, 2025 ®
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Essential3 Program Topline Results October 16, 2025
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
RADIANT topline August 4, 2025
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
CORPORATE OVERVIEW May, 2025 ®
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Praxis Precision Medicines Provides Update on Essential3 and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities
Results of operations · EX-99.1 to Form 8-K
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CORPORATE OVERVIEW November 2024 ®
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
RELUTRIGINE: EMBOLD Phase 2 Study Topline Results
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CORPORATE OVERVIEW August 2024 ®
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
4 4 >$7B 4 2 2026 Praxis is positioned to bring more innovation to patients Assets in clinical trials Commercial opportunity across the portfolio Trial readouts in next twelve months Discovery platforms to optimize drug development Cash runway into
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
UNAUDITED SELECTED FINANCIAL DATA (Amounts in thousands, except share and per share data)
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
38 2H 2023 EMBRAVE Study First Dose Cohort (Part 1) Topline Safety Results PRAX-222 SCN2A-GoF ASO KEY UPCOMING MILESTONES
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
8 2H 2023 ET Phase 3 Initiation June 2023 ET End-of-Phase 2 FDA Meeting Ulixacaltamide (PRAX-944) Essential Tremor and Parkinson’s Disease KEY UPCOMING MILESTONES
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
8 2H 2023 ET Phase 3 Initiation Mid-2023 ET End-of-Phase 2 FDA Meeting Ulixacaltamide (PRAX-944) Essential Tremor and Parkinson’s Disease KEY UPCOMING MILESTONES
Regulation FD disclosure · EX-99.1 to Form 8-K
ULIXACALTAMIDE (PRAX-944) ESSENTIAL1 ESSENTIAL TREMOR TOPLINE RESULTS March 2023
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
8 4Q 2023 Ph 2 PD Study Topline Results 1Q 2023 Ph 2b ET Essential1 Study Topline Results Ulixacaltamide (PRAX-944) Essential Tremor and Parkinson’s Disease KEY UPCOMING MILESTONES
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2022 Financial Results
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
29 >1M w/ Refractory Seizures We aim to address unmet need in the $3B+ US common epilepsy market Source: CDC, EvaluatePharma; Tang F. et al. Front. Neurol. (2017) 3.5M US Prevalence $3B+ US Common Epilepsy Market Opportunity
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K